Ryan Min
YOU?
Author Swipe
View article: First-in-Human Evaluation of Site-Specifically Labeled<sup>89</sup>Zr-Pertuzumab in Patients with HER2-Positive Breast Cancer
First-in-Human Evaluation of Site-Specifically Labeled<sup>89</sup>Zr-Pertuzumab in Patients with HER2-Positive Breast Cancer Open
Radioimmunoconjugates targeting human epidermal growth factor receptor 2 (HER2) have shown potential to noninvasively visualize HER2-positive tumors. However, the stochastic approach that has been traditionally used to radiolabel these ant…
View article: CD38-targeted Immuno-PET of Multiple Myeloma: From Xenograft Models to First-in-Human Imaging
CD38-targeted Immuno-PET of Multiple Myeloma: From Xenograft Models to First-in-Human Imaging Open
Background Current measurements of multiple myeloma disease burden are suboptimal. Daratumumab is a monoclonal antibody that targets CD38, an antigen expressed on nearly all myeloma cells. Purpose To demonstrate preclinical and first-in-hu…